文献速递病毒性肝炎

精神卫生机构、监狱及药物与酒精设施等重点场所的丙型肝炎即时检验——PROMPt研究

Point-of-Care Testing for Hepatitis C in the Priority Settings of Mental Health, Prisons, and Drug and Alcohol Facilities-the PROMPt Study.
PubMed 文献 · Clin Infect Dis · 2024-01-01

该研究在澳大利亚3类重点场所(入监监狱、精神科住院部、酒精及其他药物住院部)开展干预性队列研究,比较丙肝抗体和RNA即时检验(POCT)与历史对照的检验率、治疗衔接和可接受性。共1549人接受抗体检测,抗体阳性率17%,其中RNA阳性率21%;抗体检测率提高2.57倍,RNA检测率提高1.62倍,治疗接受率86% vs 61%(P=.01)。

要点

  • 在监狱、精神科和药物酒精住院部,丙肝抗体和RNA即时检验使抗体检测率提高2.57倍、RNA检测率提高1.62倍。
  • 丙肝抗体阳性者中21%为RNA阳性,POCT干预期间治疗接受率为86%(47/55),历史对照为61%(27/44),P=.01。
  • 该检验模式对多数参与者具有高度可接受性。

核心结论

  • 在3类重点场所中,使用丙肝抗体和RNA即时检验提高了检测率、治疗接受率和医疗衔接,且该检验模式对多数参与者高度可接受。

研究设计与样本

  • 在澳大利亚一所入监监狱、精神科住院服务机构和酒精及其他药物住院部开展干预性队列研究,入组时间为2020年10月至2021年12月。
  • 采用SD Bioline HCV抗体指尖采血试纸和反射性Xpert HCV病毒载量指尖采血试验(毛细管血)进行丙肝即时检验。
  • 在每个场所对 preceding 12个月(原文如此)的丙肝检测和治疗数据进行回顾性审计,作为历史对照。

主要发现

  • 共1549名参与者接受丙肝抗体检测,17%(264/1549)抗体阳性,其中21%(55/264)HCV RNA阳性。
  • 与历史对照相比,研究干预期间所有场所每年检测率:抗体检测提高2.57倍(率比2.57,95%CI 2.32-2.85),RNA检测提高1.62倍(率比1.62,95%CI 1.31-2.01)。
  • POCT干预期间治疗接受率为86%(47/55),历史对照为61%(27/44),P=.01。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A barrier to hepatitis C virus (HCV) cure is conventional testing. The aim of this study was to evaluate the effect of HCV antibody and RNA point-of-care testing (POCT) on testing rates, linkage to care, treatment, and acceptability of testing in 3 priority settings in Australia. METHODS: Participants were enrolled in an interventional cohort study at a reception prison, inpatient mental health service, and inpatient alcohol and other drug unit, between October 2020 and December 2021. HCV POCT was performed using SD Bioline HCV antibody fingerstick test and a reflexive Xpert HCV Viral Load Fingerstick test using capillary blood samples. A retrospective audit of HCV testing and treatment data was performed at each site for the preceding 12-month period to generate a historical control. RESULTS: A total of 1549 participants received a HCV antibody test with 17% (264 of 1549) receiving a positive result, of whom 21% (55 of 264) tested HCV RNA positive. Across all settings the rate of testing per year significantly increased between the historical controls and the study intervention period by 2.57 fold (rate ratio, 2.57 [95% confidence interval, 2.32-2.85]) for HCV antibody testing and 1.62 (rate ratio, 1.62 [95% confidence interval, 1.31-2.01]) for RNA testing. Treatment uptake was higher during the POCT intervention (86% [47 of 55]; P = .01) compared to the historical controls (61% [27 of 44]). CONCLUSIONS: This study demonstrated across 3 settings that the use of HCV antibody and RNA POCT increased testing rates, treatment uptake, and linkage to care. The testing model was highly acceptable for most participants. CLINICAL TRIALS REGISTRATION: ACTRN-12621001578897.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. McCartney EM, Ralton L, Dawe J, et al. Point-of-Care Testing for Hepatitis C in the Priority Settings of Mental Health, Prisons, and Drug and Alcohol Facilities-the PROMPt Study. Clin Infect Dis. 2024. PMID: 38513072. doi:10.1093/cid/ciae155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。